ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

Carton, Charlotte; Gareth Evans, D.; Blanco, Ignacio; E. Friedrich, Reinhard; E. Ferner, Rosalie; Farschtschi, Said; Salvador, Hector; A. Azizi, Amedeo; Mautner, Victor; Röhl, Claas; Peltonen, Sirkku; Stivaros, Stavros; Legius, Eric; Oostenbrink, Rianne; Brunet, Joan; Van Calenbergh, Frank; Cassiman, Cathérine; Czech, Thomas; José Gavarrete de León, María; Giele, Henk; M.D. Henley, Susie; Lázaro, Conxi; Lipkovskaya, Vera; R. Maher, Eamonn; Martín, Vanessa; Mathijssen, I.M.J.; Opocher, Enrico; Elisabete Pires, Ana; Pletschko, Thomas; Poupaki, Eirene; Ridola, Vita; B. Rietman, André; Rosenbaum, Thorsten; Santhouse, Alastair; Sehested, Astrid; Simmons, Ian; Taal, Walter; Wagner, Anja

doi:10.1016/j.eclinm.2022.101818

Public

ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

Published in EClinicalMedicine • Jan 13, 2023

Authors:

Charlotte Carton

D. Gareth Evans

Ignacio Blanco

Abstract

Background: Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder, predisposing development of benign and malignant tumours. Given the oncogenic potential, long-term surveillance is important in patients with NF1. Proposals for NF1 care and its specific manifestations have been developed,...

Subject

Medicine

Guideline

Neurofibromatosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!